Vascular Biogenics (NASDAQ:VBLT – Get Free Report) and Eyenovia (NASDAQ:EYEN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.
Volatility and Risk
Vascular Biogenics has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Eyenovia has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500.
This table compares Vascular Biogenics and Eyenovia’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
Earnings and Valuation
This table compares Vascular Biogenics and Eyenovia’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Vascular Biogenics||$660,000.00||25.28||-$32.30 million||($0.21)||-1.02|
|Eyenovia||$14.00 million||4.80||-$28.01 million||($0.69)||-2.55|
Eyenovia has higher revenue and earnings than Vascular Biogenics. Eyenovia is trading at a lower price-to-earnings ratio than Vascular Biogenics, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings for Vascular Biogenics and Eyenovia, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Eyenovia has a consensus target price of $12.00, suggesting a potential upside of 581.82%. Given Eyenovia’s higher probable upside, analysts plainly believe Eyenovia is more favorable than Vascular Biogenics.
Eyenovia beats Vascular Biogenics on 7 of the 12 factors compared between the two stocks.
About Vascular Biogenics
Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.
Eyenovia, Inc., a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi in rest of Asia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.